3. Katholieke Universiteit Leuven
Karen Vanhoorelbeke group:
go to group
Xavier Bossuyt:
go to page
Nick Geukens:
go to page
PharmaAbs:
go to website
Expertise, Role and Activity
Karen Vanhoorelbeke
Prof Karen Vanhoorelbeke, co-founder of PharmAbs (the KU Leuven Antibody Center, that focuses on characterization, development and production of antibody-based molecules) is expert in identifying, profiling and cloning auto-antibodies in/from (auto-immune) patients, crucial for the detailed characterization of the atherosclerotic plaque-specific antibody response in CVD patients in WP2 in collaboration with ULEI. Prof Vanhoorelbeke recently started to apply universal chimeric antigen receptor (UniCAR) and reverse CAR (RevCAR) T-cell therapies for the treatment of autoimmune diseases in collaboration with Prof Bachmann, director at the HZDR, the inventor of this unique technology. This novel technological solution will form the core of WP4 aimed at developing a novel, effective therapy for the treatment of atherosclerosis (associated CVD).
Xavier Bossuyt
Prof Bossuyt, co-founder of PharmAbs, is also expert in identifying, profiling and cloning auto-antibodies in/from (auto-immune) patients and has access to state-of-the-art mass spectrometry facilities crucial for novel autoantigen discovery.
Nick Geukens
Dr. Nick Geukens is Manager at PharmAbs.
All the Consortium
